
https://www.science.org/content/blog-post/another-ai-generated-drug
# Article Title (January 2020)

## 1. SUMMARY
The article analyzes early press claims of the "first AI-generated drug" (DSP-1181) entering human trials, a collaboration between Sumitomo and Exscientia targeting OCD. The compound is a long-acting 5-HT1a agonist discovered using Exscientia's algorithms. While the companies emphasized a remarkably rapid 12-month timeline to reach clinical trials—faster than the typical 2-3 years—the article raises several critical doubts about whether this represents a drug discovery revolution.

The core argument is that preclinical optimization was never the primary bottleneck in drug development. The 5-HT1a target for anxiety and OCD had been well-established for decades (the author cites a 2009 review). Many existing 5-HT1a compounds like azapirones, 8-OH DPAT, flibanserin, befiradol, repinotan, and piclozotan had already been explored in humans, often for various psychiatric and CNS conditions, with mixed outcomes and several clinical failures. The article questions the novelty of targeting 5-HT1a and speculates that DSP-1181 may resemble existing chemical matter, noting that no structure had yet been published and Exscientia's patents focus on machine learning techniques rather than novel molecules. For CNS drugs, where efficacy and safety predictions are extremely difficult, the author argues that AI provides insufficient data for meaningful answers. The author concludes that speeding up preclinical optimization does little when human trials remain a "black-box shredder" with high failure rates (~90–95% for CNS), and AI has not yet changed the fundamental uncertainties.

## 2. HISTORY
Following the article's publication in January 2020, DSP-1181's Phase I trial progress was later disclosed by Sumitomo Dainippon Pharma. In September 2022, the company announced that DSP-1181 had not demonstrated a sufficiently favorable profile to advance, and development would be discontinued. This outcome aligns with the article's skeptical warnings about high CNS trial failure rates when moving into human trials from preclinical stages.

Exscientia continued its work on AI-enabled drug discovery. The company went public in October 2021 and pursued additional drug candidates, including molecules developed with partners such as Bristol Myers Squibb, Sanofi, and GT Apeiron Therapeutics. Some of these programs advanced into clinical phases, covering oncology and immunology, although oncology candidates like EXS-21546 (A2a receptor antagonist) were later discontinued. Exscientia also initiated trials for internally developed compounds like EXS-74539 (a LSD1 inhibitor for acute myeloid leukemia and small-cell lung cancer) and EXS-4318 (a PKC-theta inhibitor for inflammatory bowel disease). By late 2024, Exscientia had several clinical-stage programs, often progressing more swiftly to IND than traditional timelines. However, the broader context shows that even when AI accelerates preclinical timelines, clinical success rates and regulatory approvals remain challenging.

Within the AI drug discovery sector, other firms like Insilico Medicine, Recursion Pharmaceuticals, and Schrödinger advanced their platforms. Insilico, for example, progressed AI-designed molecules into clinical trials, though one was later discontinued. Recursion brought an AI-nominated drug candidate for cerebral cavernous malformation into Phase II and trimmed other programs. These examples continued to fuel debate over the extent to which AI meaningfully improves success rates beyond speed in early-stage discovery.

Alongside AI-discovered molecules, a parallel trend of AI-designed formulations, biomarkers, and clinical trial optimization gained prominence, with companies concentrating on better patient stratification and dosing decisions using machine learning. Regulatory awareness also grew, including FDA workshops and guidance considerations around AI in drug development.

Thus, the "first AI-generated drug" claim from 2020 did not result in an approved, clinically impactful medicine. Instead, it highlighted that AI acceleration in preclinical phases can reduce discovery timelines, yet it does not eliminate the fundamental uncertainties and high attrition rates of CNS and other disease areas once compounds enter human trials. The DSP-1181 case became an early, cautionary example of AI's promise confronted with clinical reality.

## 3. PREDICTIONS
- **The preclinical speedup would prove minor in the overall drug development timeline.**
  - ✅ Accurate. DSP-1181 advanced to Phase I quickly, but its discontinuation in September 2022 showed that the major bottleneck lies in demonstrating favorable safety/efficacy in human trials, not in preclinical optimization.

- **DSP-1181 would likely enter the same "black-box shredder" as conventional CNS programs, with >90% (likely ~95%) chance of failure.**
  - ✅ Confirmed. The program's termination in 2022 validated the prediction that high attrition rates in CNS indications would persist despite AI involvement.

- **AI had not yet changed the fundamental inability to predict CNS efficacy or unexpected toxicity.**
  - ✅ Broadly accurate. DSP-1181 was discontinued after failing to meet advancement criteria in human trials, reflecting the difficulty of translating AI-designed preclinical candidates into successful clinical outcomes in CNS. Other AI-discovered clinical candidates beyond CNS have also experienced discontinuations, reinforcing that AI has not eliminated later-stage failures.

- **A more conventional program targeting 5-HT1a might have taken 2-3 years to reach the clinic, and this project at best "saved a few months" while still hitting the same clinical uncertainties.**
  - ⚠️ Partially supported, but nuanced. A one-year IND timeline is still notably faster than many conventional programs. However, this speed did not meaningfully shorten the overall time to success or approval because the project was discontinued early. The main premise—that speeding up preclinical steps might not accelerate the whole pathway—was substantiated.

- **The 5-HT1a target had already been extensively explored and that AI would not overcome existing complexities.**
  - ✅ Accurate. The field continued to grapple with the same target- and disease-related uncertainties, and no breakthrough 5-HT1a drug with AI origins has yet emerged as a widely adopted therapy.

- **The claim of being the "first AI-generated drug" rested more on publicity than on scientific innovation or clinical success.**
  - ✅ Validated. DSP-1181 did not become a clinically used drug, nor did it revolutionize discovery. Subsequent discourse highlighted similarly titled claims by other companies, suggesting the "first" framing was more of a promotional milestone than a game-changer.

## 4. INTEREST 
Rating: **8/10**
The article aged well, offering sharp, evidence-based skepticism of a widely publicized "AI-first" claim and correctly forecasting that DSP-1181 would likely fail in trials while clarifying that preclinical speed isn't the main bottleneck in drug development.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20200131-another-ai-generated-drug.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_